

Please click here <sup>[1]</sup> to find the correct answers to the self-assessment survey (to be uploaded).

**Presentations:**

1. Concept of therapeutic drug monitoring (TDM) <sup>[2]</sup>

*Prof Dr Branislava Miljković<sup>[3]</sup>, Faculty of Pharmacy, University of Belgrade, Serbia*

2. Practical consideration to TDM <sup>[4]</sup>

*Prof Dr Azucena Aldaz Pastor<sup>[5]</sup>, Clínica Universidad de Navarra, Spain*

3. Population pharmacokinetic analysis of TDM in optimising therapy <sup>[6]</sup>

*Prof Dr Kees Neef<sup>[7]</sup>, EAHP Director of Education, Science & Research, Maastricht University Medical Center+, The Netherlands*

<sup>[8]</sup>

4. TDM and dose optimisation of antibiotics and antifungals <sup>[8]</sup>

*Prof Dr Daniel J. Touw<sup>[9]</sup>\*, University Medical Center Groningen, The Netherlands*

5. TDM and dose optimisation of antiepileptic and antipsychotic drugs <sup>[10]</sup>

*Prof Dr Christoph Hiemke<sup>[11]</sup>, University Medical Center Mainz, Germany*

6. An overview of therapeutic drug monitoring software <sup>[12]</sup>

*Nieko Punt<sup>[13]</sup>\*, Medimatics, Maastricht, The Netherlands*

7. TDM and dose optimisation of immunosuppressive and oncolytic agents <sup>[14]</sup>

*Dr Erik van Maarseveen<sup>[15]</sup>, University Medical Center Utrecht, The Netherlands*

8. Workshop. Clinical cases on dose adjustments based on TDM of immunosuppressives and oncolytic agents <sup>[16]</sup>

*Dr Erik van Maarseveen<sup>[15]</sup>, University Medical Center Utrecht, The Netherlands*

<sup>[17]</sup>

9. Workshop ?Business case? on implementation of TDM in hospital <sup>[17]</sup>

*Antonio Gouveia<sup>[18]</sup>, Instituto Portugues de Oncologia de Lisboa, Portugal*

10. Workshop. Clinical cases on dose adjustments based on TDM of antibiotics and antifungals <sup>[19]</sup>

*Prof Dr Daniel J. Touw<sup>[9]</sup>\*, University Medical Center Groningen, The Netherlands*

11. Workshop. Clinical cases on dose adjustments based on TDM of antiepileptic and antipsychotic drugs <sup>[20]</sup>

*Prof Dr Christoph Hiemke<sup>[11]</sup>, University Medical Center Mainz, Germany*

## Links

[1] <http://www.eahp.eu/content/seminar-2-2018-academy-seminars-individual-learning-assessment-questionnaire>

[2] [https://www.eahp.eu/sites/default/files/1.\\_concept\\_of\\_therapeutic\\_drug\\_monitoring\\_tdm.pdf](https://www.eahp.eu/sites/default/files/1._concept_of_therapeutic_drug_monitoring_tdm.pdf)

[3] <http://www.eahp.eu/content/prof-branislava-miljkovi%C4%87>

[4] [https://www.eahp.eu/sites/default/files/2.\\_practical\\_consideration\\_to\\_tdm.pdf](https://www.eahp.eu/sites/default/files/2._practical_consideration_to_tdm.pdf)

[5] <http://www.eahp.eu/content/prof-dr-azucena-aldaz-pastor>

[6] [https://www.eahp.eu/sites/default/files/3.\\_population\\_pharmacokinetic\\_analysis\\_of\\_tdm\\_in\\_optimising\\_therapy.pdf](https://www.eahp.eu/sites/default/files/3._population_pharmacokinetic_analysis_of_tdm_in_optimising_therapy.pdf)

[7] <http://www.eahp.eu/content/kees-neef>

[8] [https://www.eahp.eu/sites/default/files/4.\\_tdm\\_and\\_dose\\_optimisation\\_of\\_antibiotics\\_and\\_antifungals.pdf](https://www.eahp.eu/sites/default/files/4._tdm_and_dose_optimisation_of_antibiotics_and_antifungals.pdf)

[9] <http://www.eahp.eu/content/prof-dr-daniel-j-touw>

[10] [https://www.eahp.eu/sites/default/files/5.\\_tdm\\_and\\_dose\\_optimisation\\_ofantiepileptic\\_and\\_antipsychotic\\_drugs.pdf](https://www.eahp.eu/sites/default/files/5._tdm_and_dose_optimisation_ofantiepileptic_and_antipsychotic_drugs.pdf)

[11] <http://www.eahp.eu/content/prof-dr-christoph-hiemke>

[12] [https://www.eahp.eu/sites/default/files/6.\\_an\\_overview\\_of\\_therapeutic\\_drug\\_monitoring\\_software\\_0.pdf](https://www.eahp.eu/sites/default/files/6._an_overview_of_therapeutic_drug_monitoring_software_0.pdf)

[13] <http://www.eahp.eu/content/nieko-punt>

[14] [https://www.eahp.eu/sites/default/files/7.\\_tdm\\_and\\_dose\\_optimisation\\_of\\_immunosuppressive\\_and\\_oncolytic\\_agents.pdf](https://www.eahp.eu/sites/default/files/7._tdm_and_dose_optimisation_of_immunosuppressive_and_oncolytic_agents.pdf)

[15] <http://www.eahp.eu/content/dr-erik-van-maarseveen>

[16] [https://www.eahp.eu/sites/default/files/8.\\_workshop.\\_clinical\\_cases\\_on\\_dose\\_adjustments\\_based\\_on\\_tdm\\_of\\_immunosuppressants.pdf](https://www.eahp.eu/sites/default/files/8._workshop._clinical_cases_on_dose_adjustments_based_on_tdm_of_immunosuppressants.pdf)

[17] [https://www.eahp.eu/sites/default/files/9.\\_workshop\\_business\\_case\\_on\\_implementation\\_of\\_tdm\\_in\\_hospital.pdf](https://www.eahp.eu/sites/default/files/9._workshop_business_case_on_implementation_of_tdm_in_hospital.pdf)

[18] <http://www.eahp.eu/content/antonio-gouveia>

[19] [https://www.eahp.eu/sites/default/files/10.\\_clinical\\_cases\\_on\\_dose\\_adjustments\\_based\\_on\\_tdm\\_of\\_antibiotics\\_and\\_antifungals.pdf](https://www.eahp.eu/sites/default/files/10._clinical_cases_on_dose_adjustments_based_on_tdm_of_antibiotics_and_antifungals.pdf)

[20] [https://www.eahp.eu/sites/default/files/11.\\_clinical\\_cases\\_on\\_dose\\_adjustments\\_based\\_on\\_tdm\\_ofantiepileptic\\_drugs.pdf](https://www.eahp.eu/sites/default/files/11._clinical_cases_on_dose_adjustments_based_on_tdm_ofantiepileptic_drugs.pdf)